Data from first (2009) and second (2017) NEDROP studies
| 2009 | 2017 | |
| Live born babies | 1662 | 1492 |
| GA 28.0–32.0 | 1303 | 1092 |
| GA 25.0 to <28.0 | 313 | 331 |
| GA <25.0 | 46 | 69 |
| Eligible for screening* | 2033 | 1287 |
| Fully screened | 1688 (83.0%) | 1085 (84.3%) |
| Timely first screening | 1064 (63%) | 849 (78.2%) |
| GA† | 30.1 (28.6–31.4) | 29 (27.3–30.4) |
| BW† | 1320 (1050–1560) | 1150 (935–1350) |
| Infants transferred | 822 | 906 |
| Lost to follow-up after transfer | 189/822 (23.0%) | 22/902 (2.4%)‡ |
| Number of screenings total | 3891 | 3750 |
| Number of screenings no ROP | 2402 | 1981 |
| Number of screenings with ROP | 1489 | 1769 |
| ROP total | 324 | 305 |
| Incidence among live births | 19.5% | 20.4% |
| Type 1 ROP§ | 21 | 38 |
| Type 2 ROP§ | 10 | 15 |
| Stage 3 or higher | 30 | 49 |
| Treatment | 17 | 39 |
| Retinal detachment | 6 | 3 |
*According to Dutch paediatricians.
†Median (IQR) of screened infants.
‡This group includes only infants who survived and met the new screening criteria.
§Incomplete data on plus disease for 2009.
BW, birth weight (g); GA, gestational age (weeks); ROP, retinopathy of prematurity.